Skip to main content
TipRanks
Go Ultimate75% OFF

Chia Tai Enterprises International (3839) AI Stock Analysis

0 Followers
HK:3839

Chia Tai Enterprises International

(HKEX:3839)

Select Model
Rating:70Outperform
Price Target:HKD 8.50â–²(17.40% Upside)
Action:reiterated
Date:11/07/26

The overall score of 70 is primarily driven by robust financial performance and an attractive valuation, tempered significantly by weak technical momentum. The company has demonstrated exceptional top-line growth, successful cash flow turnaround, and maintains a highly stable balance sheet, making its 9.89 P/E ratio compelling. However, the stock is technically pressured, trading below all major moving averages with a negative MACD, indicating that while fundamentals are strong, prevailing market sentiment remains bearish.

Positive Factors
Revenue and Profitability ReboundThe sharp 2025 revenue rebound, together with improved operating and net margins, indicates stronger recent business execution and renewed earnings capacity. If sustained, this scale and profitability improvement can support reinvestment, strengthen the company’s position in animal health markets, and improve resilience over the next several quarters.
Negative Factors
Gross Margin CompressionThe sustained gap between the recent gross margin and earlier levels signals pressure on pricing, product mix or costs, even after the 2025 earnings rebound. Lower gross profitability leaves less room to absorb operating expenses and market volatility, making future earnings more dependent on volume growth and cost control.

Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-10%0%10%20%30%40%50%60%HK:3839+12.25%EWH+4.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 270.48M
Dividend Yield
―
Average Volume (3M)
62.45K
Price to Earnings (P/E)
11.3
Beta (1Y)
1.08
Revenue Growth
-22.78%
EPS Growth
-32.03%
Country
Hong Kong
Employees
900
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Chia Tai Enterprises International Business Overview & Revenue Model

Company Description

CPBIO Holding Company Limited produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operations are divided into tw...

How the Company Makes Money

The company makes money primarily by selling and distributing animal health and related agribusiness products and services. Key revenue streams typically include: (1) product sales to farms, distributors, and veterinary channels (e.g., animal health...

Chia Tai Enterprises International Financial Statement Overview

Summary

The company shows strong fundamental health with explosive revenue growth and a return to solid profitability in 2025. It boasts a conservative balance sheet with a low debt-to-equity ratio of 0.17 and improving free cash flow generation, though a multi-year trend of gross margin compression remains a notable headwind.

Income Statement

78Positive

Balance Sheet

82Very Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue424.03M536.71M307.75M173.98M159.24M142.41M
Gross Profit70.39M77.55M48.93M30.18M39.19M34.76M
EBITDA38.91M48.38M19.29M11.29M5.17M12.52M
Net Income24.44M32.10M11.17M2.55M-6.68M19.56M
Balance Sheet
Total Assets505.27M461.60M422.21M377.37M350.58M365.22M
Cash, Cash Equivalents and Short-Term Investments37.25M39.83M32.38M37.61M30.86M31.09M
Total Debt75.56M47.87M69.17M78.17M49.10M42.61M
Total Liabilities179.05M153.76M161.70M125.36M94.83M81.69M
Stockholders Equity293.73M277.11M234.77M228.43M230.85M253.06M
Cash Flow
Free Cash Flow028.04M-2.56M-27.17M-10.38M-28.46M
Operating Cash Flow034.33M11.29M-16.06M5.63M-10.91M
Investing Cash Flow0-2.79M-9.27M-7.14M-15.64M-9.84M
Financing Cash Flow0-24.38M-7.07M30.23M10.38M19.36M

Chia Tai Enterprises International Technical Analysis

Technical Analysis SentimentNegative
Last Price7.24

Price Trends

50DMA7.91Negative
100DMA8.42Negative
200DMA7.95Negative

Market Momentum

MACD-0.13Negative
RSI32.94Neutral
STOCH79.64Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3839, the sentiment is Negative. The current price of 7.24 is below the 20-day moving average (MA) of 7.62, below the 50-day MA of 7.91, and below the 200-day MA of 7.95, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 32.94 is Neutral, neither overbought nor oversold. The STOCH value of 79.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3839.

Chia Tai Enterprises International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:3839 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3839HK:383970OutperformHKD 1.94B11.307.14%―-22.78%-32.03%
HK:0950HK:095068NeutralHKD 588.84M3.568.02%5.75%7.05%22.46%
HK:0512HK:051262NeutralHKD 14.78B12.676.61%4.16%7.35%-45.49%
HK:0897HK:089759NeutralHKD 390.03M100.000.34%―-8.30%-44.44%
HK:0570HK:057058NeutralHKD 5.59B-4.47-4.98%0.32%-15.80%-298.94%
HK:3933HK:393354NeutralHKD 14.09B21.073.12%6.89%-12.86%-83.10%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%50%HK:3839HK:3933HK:0570HK:0897HK:0950HK:0512Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:3839 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:3839Chia Tai Enterprises International 7.240.9815.65%
HK:3933The United Laboratories International6.88-4.75-40.80%
HK:0570China Traditional Chinese Medicine Holdings Co 1.08-1.23-53.03%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.06-14.29%
HK:0950Lee's Pharmaceutical Holdings Limited1.00-0.60-37.42%
HK:0512Grand Pharmaceutical Group Limited4.06-3.85-48.65%

Chia Tai Enterprises International Corporate Events

CPBIO Reports Unaudited Nine-Month 2026 Results

Nov 11, 2026

CPBIO Holding Company Limited reported unaudited consolidated results for the nine months ended 30 September 2026. Revenue was US$331.617 million, down from US$430.536 million a year earlier, while gross profit fell to US$53.739 million from US$59.59...

CPBIO Shareholders Approve 2026 HOEL Purchase Agreement

Nov 4, 2026

CPBIO Holding Company Limited’s release does not provide information on its industry, products or market focus.Shareholders approved the 2026 Master HOEL Purchase Agreement, related transactions and annual caps at a special general meeting on 4 Novem...

CPBIO Sets November Board Meeting to Approve Nine-Month Unaudited Results

Oct 30, 2026

CPBIO Holding Company Limited has scheduled a board meeting for 11 November 2026 to review and approve the unaudited financial results of the company and its subsidiaries for the nine months ended 30 September 2026. The announcement signals the upcom...

CPBIO Calls Special Meeting to Approve HOEL Supply Agreement Caps

Oct 13, 2026

CPBIO Holding Company Limited has called a special general meeting in Hong Kong on 4 November 2026 for shareholders to vote on approving and ratifying the 2026 Master HOEL Purchase Agreement. The agreement covers the ongoing supply of CPBIO Products...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026